Reducing Neoplasia Recurrence After Endoscopic Resection of Large Colorectal Polyps
Recruiting · NCT06271941 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Large (≥20mm) colorectal polyps often harbor areas of advanced neoplasia, making them immediate colorectal cancer (CRC) precursors. Such polyps have to be completely removed to prevent CRC and to avoid surgery and/or adjuvant therapy. The laterally spreading lesions (LSLs) are removed via endoscopic mucosal resection (EMR). However, recurrence is common. New techniques for LSL resection (hybrid argon plasma coagulation (h-APC) margin and base ablation) have shown a reduction in recurrence following the interventions. We hypothesize that performing hybrid argon plasma coagulation (h-APC) margin and base ablation during EMR of large (≥20mm) colorectal LSLs will lead to lower rates of lesion recurrence compared to Snare tip soft coagulation (STSC) margin ablation.
Who can take part
Inclusion criteria
- adult ≥18 years old
- patients undergoing EMR for a large (≥20mm) colorectal LSL
- patients providing written and informed consent for study participation.
Exclusion criteria
- inflammatory bowel disease;
- non-elective colonoscopy;
- poor general health (American Society of Anesthesiologists classification \>III);
- coagulopathy or thrombocytopenia (international normalized ratio ≥1.5 or platelets \<50 x 109/L);
- pedunculated polyps (Paris class Ip, Isp);
- overt signs of deep submucosal invasive cancer (JNET 3);
- biopsy proven invasive carcinoma in a potential study polyp.
- Pregnant women
Where it is running
1 location listed.
- Centre Hospitalier de l'Université de Montréal - Montreal, Quebec, Canada